{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:30:11Z","timestamp":1775064611766,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10388-019-00709-5","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T12:28:47Z","timestamp":1577968127000},"page":"127-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Masashi","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-5119","authenticated-orcid":false,"given":"Yasuhiro","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoaki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Noma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Sakurama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Katsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"issue":"8","key":"709_CR1","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00268-005-0462-6","volume":"30","author":"H Shimada","year":"2006","unstructured":"Shimada H, Okazumi S, Matsubara H, et al. Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg. 2006;30(8):1441\u20139.","journal-title":"World J Surg"},{"issue":"7","key":"709_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/BF03218018","volume":"47","author":"Y Ichiyoshi","year":"1999","unstructured":"Ichiyoshi Y, Kawahara H, Taga S, et al. Indications and operative techniques for combined aortoesophageal resection. Jpn J Thorac Cardiovasc Surg. 1999;47(7):318\u201324.","journal-title":"Jpn J Thorac Cardiovasc Surg."},{"issue":"1","key":"709_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-018-0641-9","volume":"16","author":"Y Kitagawa","year":"2018","unstructured":"Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2018;16(1):1\u201324.","journal-title":"Esophagus"},{"issue":"2","key":"709_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/ags3.12222","volume":"3","author":"T Makino","year":"2019","unstructured":"Makino T, Yamasaki M, Tanaka K, et al. Treatment and clinical outcome of clinical T4 esophageal cancer: a systematic review. Ann Gastroenterol Surg. 2019;3(2):169\u201380.","journal-title":"Ann Gastroenterol Surg."},{"issue":"7","key":"709_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/jjco\/hyt061","volume":"43","author":"K Nakamura","year":"2013","unstructured":"Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43(7):752\u20135.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"709_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10388-018-0627-7","volume":"15","author":"H Okamoto","year":"2018","unstructured":"Okamoto H, Taniyama Y, Sakurai T, et al. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. Esophagus. 2018;15(4):281\u20135.","journal-title":"Esophagus"},{"issue":"3","key":"709_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00280-018-03764-4","volume":"83","author":"K Sasaki","year":"2019","unstructured":"Sasaki K, Uchikado Y, Omoto I, et al. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2019;83(3):581\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"709_CR8","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2016","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Hoboken: Wiley; 2016."},{"issue":"1","key":"709_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","volume":"14","author":"Esophageal S Japan","year":"2017","unstructured":"Japan Esophageal S. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14(1):1\u201336.","journal-title":"Esophagus."},{"key":"709_CR10","unstructured":"Health UDo, Services H. Common Terminology Criteria for Adverse Events (CTCAE) v5. 0. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 27 Nov 2017"},{"key":"709_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-4471-4354-3_3","volume-title":"The Clavien-Dindo classification of surgical complications. Treatment of postoperative complications after digestive surgery","author":"D Dindo","year":"2014","unstructured":"Dindo D. The Clavien-Dindo classification of surgical complications. Treatment of postoperative complications after digestive surgery. Berlin: Springer; 2014. p. 13\u20137."},{"issue":"3","key":"709_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5761\/atcs.ra.11.01676","volume":"17","author":"T Makino","year":"2011","unstructured":"Makino T, Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011;17(3):221\u20138.","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"5","key":"709_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/jso.23514","volume":"109","author":"Y Jeong","year":"2014","unstructured":"Jeong Y, Kim JH, Kim SB, et al. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. J Surg Oncol. 2014;109(5):472\u20137.","journal-title":"J Surg Oncol"},{"issue":"8","key":"709_CR14","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s11605-013-2269-3","volume":"17","author":"C Castoro","year":"2013","unstructured":"Castoro C, Scarpa M, Cagol M, et al. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary? J Gastrointest Surg. 2013;17(8):1375\u201381.","journal-title":"J Gastrointest Surg."},{"key":"709_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/dox141","author":"F Fujishima","year":"2018","unstructured":"Fujishima F, Taniyama Y, Nakamura Y, et al. Residual carcinoma cells after chemoradiotherapy for esophageal squamous cell carcinoma patients: striving toward appropriate judgment of biopsy. Dis Esophagus. 2018. https:\/\/doi.org\/10.1093\/dote\/dox141.","journal-title":"Dis Esophagus."},{"issue":"1","key":"709_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10388-018-0642-8","volume":"6","author":"Y Kitagawa","year":"2018","unstructured":"Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2018;6(1):25\u201343.","journal-title":"Esophagus"},{"issue":"6","key":"709_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00280-012-1853-7","volume":"69","author":"M Emi","year":"2012","unstructured":"Emi M, Hihara J, Hamai Y, et al. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. Cancer Chemother Pharmacol. 2012;69(6):1499\u2013505.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"709_CR18","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.7150\/jca.23456","volume":"9","author":"Y Tamaki","year":"2018","unstructured":"Tamaki Y, Hieda Y, Nakajima M, et al. Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil improves survival of patients with advanced esophageal cancer compared with conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil. J Cancer. 2018;9(16):2765\u201372.","journal-title":"J Cancer."},{"issue":"4","key":"709_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ijrobp.2014.03.030","volume":"89","author":"K Higuchi","year":"2014","unstructured":"Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014;89(4):872\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"709_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00280-016-3062-2","volume":"78","author":"H Satake","year":"2016","unstructured":"Satake H, Tahara M, Mochizuki S, et al. A prospective, multicenter phase I\/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 2016;78(1):91\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"709_CR21","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1002\/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.0.CO;2-H","volume":"91","author":"E Ancona","year":"2001","unstructured":"Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91(11):2165\u201374.","journal-title":"Cancer"},{"issue":"1","key":"709_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/(SICI)1096-9098(199901)70:1<25::AID-JSO5>3.0.CO;2-M","volume":"70","author":"M Yano","year":"1999","unstructured":"Yano M, Tsujinaka T, Shiozaki H, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 1999;70(1):25\u201332.","journal-title":"J Surg Oncol"},{"issue":"2","key":"709_CR23","first-page":"e4103","volume":"11","author":"N Dagoglu","year":"2019","unstructured":"Dagoglu N, Karaman S, Caglar HB, et al. Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases. Cureus. 2019;11(2):e4103.","journal-title":"Cureus."},{"key":"709_CR24","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1038\/cddis.2013.207","volume":"4","author":"K Kono","year":"2013","unstructured":"Kono K, Mimura K, Kiessling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis. 2013;4:e688.","journal-title":"Cell Death Dis."},{"issue":"11","key":"709_CR25","doi-asserted-by":"publisher","first-page":"e3125","DOI":"10.1097\/MD.0000000000003125","volume":"95","author":"Y Mohri","year":"2016","unstructured":"Mohri Y, Tanaka K, Toiyama Y, et al. Impact of preoperative neutrophil to lymphocyte ratio and postoperative infectious complications on survival after curative gastrectomy for gastric cancer: a single institutional cohort study. Medicine (Baltimore). 2016;95(11):e3125.","journal-title":"Medicine (Baltimore)."}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-019-00709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10388-019-00709-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-019-00709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:56:18Z","timestamp":1609462578000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10388-019-00709-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s10388-019-00709-5","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"8 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"All authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}